Zama launches its Protocol mainnet and will sell 10% of $ZAMA in January via the first onchain sealed-bid Dutch auction, encrypting bids with FHE.Zama launches its Protocol mainnet and will sell 10% of $ZAMA in January via the first onchain sealed-bid Dutch auction, encrypting bids with FHE.

Zama to Hold First-Ever Onchain Sealed-Bid Dutch Auction for $ZAMA After Mainnet Launch

zama1

Zama, the open-source cryptography firm best known for its work on Fully Homomorphic Encryption (FHE) for blockchain, said on Tuesday that it will launch the Zama Protocol mainnet and follow the rollout with a public token sale, a sealed-bid Dutch auction onchain that the company says will be the first of its kind.

The auction, scheduled for January with the exact date and participation details to be revealed in early January, will sell 10 percent of the $ZAMA token supply. Unlike typical token offerings that often occur before a product is live and rely on airdrops or speculative pricing, Zama plans to sell tokens to users, developers and node operators of an already-running mainnet. The company emphasized that bids will be publicly visible in price, but that bid sizes will remain confidential thanks to Zama’s own FHE technology, which encrypts bid amounts onchain.

Zama says the sealed-bid Dutch auction model has historical precedent; it was used to price Google’s IPO in 2004, and that using encryption for bid amounts will produce fairer, manipulation-resistant price discovery. The token itself will power the protocol economy: applications will pay fees to encrypt and decrypt data, while node operators will stake $ZAMA to secure the network and earn rewards.

“This token auction represents much more than a sale — it is the starting point for a confidential, compliant onchain financial system,” said Dr Rand Hindi, CEO and co-founder. “Zama makes it possible for institutions to issue, transfer, and trade assets privately on public blockchains, opening the door for the $100 trillion financial industry to migrate onchain. Zama is to blockchain what HTTPS was to the internet. We call it HTTPZ.”

Confidential Finance Push

Zama describes the Protocol as a privacy layer for existing public blockchains such as Ethereum that allows anyone to issue, transfer and trade assets confidentially while keeping transactions auditable and compliant. The company argues that institutions have long faced a trade-off between transparency and privacy, operate transparently and expose sensitive data, or protect privacy and risk regulatory non-compliance, and that its Confidential Blockchain Protocol removes that trade-off by enabling encrypted data to be processed and verified directly onchain without ever being decrypted.

At the core of Zama’s approach is Fully Homomorphic Encryption, a cryptographic technique that permits computation on encrypted data. Zama says FHE enables onchain data to remain securely encrypted against both current and future threats, including quantum attacks, while remaining publicly verifiable and composable with decentralized finance and other financial applications. In practice, anything currently done with non-confidential tokens on blockchains, Zama says, can be done confidentially on its network.

The company highlighted a range of confidential use cases that its mainnet and partners are already developing. Confidential stablecoins could enable encrypted payroll and cross-border payments that preserve privacy while embedding AML controls. Encrypted DeFi could protect swaps, lending and derivatives from front-running and data leakage. Private tokenization promises confidential LP shares and securities where investor data and positions stay encrypted yet auditable, and confidential governance could keep votes and holdings private while revealing only final tallies.

Zama’s mainnet is launching with an expanding partner ecosystem that the company says is already bringing those use cases to life. Among the projects named are Deberrys, billed as the first truly confidential auction house on blockchain; Zaiffer, a privacy-preserving DeFi provider; Orion Finance, focused on verifiable, privacy-preserving portfolio management; and tGBP, a fully collateralized confidential stablecoin pegged 1:1 to the British Pound. TokenOps, Raycash, Shiba Inu’s ecosystem, DFNS and security firm OpenZeppelin, which Zama said is collaborating on a Confidential ERC-20 token standard, were also listed as partners.

Zama boasts what it calls the world’s largest research team focused on FHE, with more than 100 cryptographers, engineers and blockchain developers. The startup has raised over $150 million from investors including Pantera Capital, Multicoin Capital, Protocol Labs, Metaplanet and Blockchange Ventures, and was recently valued at more than $1.2 billion, according to the company. The upcoming token auction is framed as a milestone on Zama’s roadmap toward enabling fully homomorphic onchain computation.

Founded by Dr. Pascal Paillier and Dr. Rand Hindi, Zama has pitched its technology as a foundational primitive for confidential finance on public blockchains, an attempt to give institutions the privacy guarantees they need while preserving auditability and regulatory compliance. The January sealed-bid Dutch auction will be the first public test of selling token supply directly on a live mainnet using the same confidential mechanisms Zama says will underpin the protocol’s future.

Market Opportunity
Everscale Logo
Everscale Price(EVER)
$0,00448
$0,00448$0,00448
+2,75%
USD
Everscale (EVER) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26